Roy Fleischmann - Concepedia

Author

Roy Fleischmann

The University of Texas Southwestern Medical Center ORCID

Also Known As

B. Kirkham, C. Molloy, D. A. Walsh, D. Gould, E. C. Keystone, F. Atzeni, Fleischmann R., Fleischmann, Roy, J. Curtis, J. Pope

481

Publications

31.8K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Southwestern Medical Center Metroplex Clinical Research Center Stanford University Pfizer (United States)

About

Roy Fleischmann is an author at The University of Texas Southwestern Medical Center specializing in medicine, rheumatology, and rheumatoid arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	29	5.9K
2	Allergy	2	2	259
3	Engineering	1	1	53
4	Health Sciences	1	1	55
5	Public Health	1	1	13

Roy Fleischmann

183

Publications

29.2K

Citations

H-Index

Page 1

	Year	Citations
A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate Michael E. Weinblatt, Joel M. Kremer, Arthur D. Bankhurst, New England Journal of Medicine	1999	2.1K
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis Joan M. Bathon, Richard W. Martin, Roy Fleischmann, New England Journal of Medicine	2000	1.8K
Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein Larry W. Moreland, Scott W. Baumgartner, Michael Schiff, New England Journal of Medicine ImmunologyImmune RegulationPathologySoluble Tnf ReceptorImmune System	1997	1.6K
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial Paul Emery, Roy Fleischmann, Anna Filipowicz‐Sosnowska, Arthritis & Rheumatism	2006	1K
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis Roy Fleischmann, Joel M. Kremer, John J. Cush, New England Journal of Medicine	2012	1K
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, New England Journal of Medicine	2012	922
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial John C. Davis, Désirée van der Heijde, Jürgen Braun, Arthritis & Rheumatism	2003	762
Tofacitinib versus Methotrexate in Rheumatoid Arthritis Eun Bong Lee, Roy Fleischmann, Stephen Hall, New England Journal of Medicine	2014	761
Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes Mark C. Genovese, Joan M. Bathon, Richard W. Martin, Arthritis & Rheumatism	2002	731
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst, The Lancet Respiratory Medicine Autoimmune DiseaseSystemic SclerodermaImmunologySystemic SclerosisMultiple Sclerosis	2020	612

Page 1